Replimune Group Files Q1 FY25 10-Q
Ticker: REPL · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Replimune's Q1 FY25 10-Q is in, check financials for latest updates.
AI Summary
Replimune Group, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company, based in Woburn, MA, is involved in the biological products sector. Key financial data and operational updates for the first quarter of fiscal year 2025 are detailed in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and operational status of Replimune Group, Inc., crucial for understanding its ongoing development and market position.
Risk Assessment
Risk Level: medium — As a biotechnology company, Replimune faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 06-30 2025 — Fiscal Year End (Indicates the end of the fiscal year for which the report is relevant.)
- 2024-04-01 to 2024-06-30 — Reporting Period (Specifies the dates covered by the financial information in the 10-Q.)
Key Players & Entities
- Replimune Group, Inc. (company) — Filer of the 10-Q
- Woburn, MA (location) — Company's business and mailing address
- June 30, 2024 (date) — End of the reporting period
- 20240808 (date) — Filing date
FAQ
What is the primary business of Replimune Group, Inc. according to the filing?
Replimune Group, Inc. is primarily involved in the biological products sector, specifically biological products (no diagnostic substances).
What is the reporting period covered by this 10-Q filing?
This 10-Q filing covers the period from April 1, 2024, to June 30, 2024.
When was this 10-Q form filed with the SEC?
This 10-Q form was filed on August 8, 2024.
Where is Replimune Group, Inc. located?
Replimune Group, Inc. is located in Woburn, MA, with its business and mailing address at 500 Unicorn Park.
What is the SEC file number for Replimune Group, Inc.?
The SEC file number for Replimune Group, Inc. is 001-38596.
Filing Stats: 4,667 words · 19 min read · ~16 pages · Grade level 15.5 · Accepted 2024-08-08 08:06:36
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Market
Filing Documents
- repl-20240630.htm (10-Q) — 1258KB
- repl-6302024x10qxex311.htm (EX-31.1) — 11KB
- repl-6302024x10qxex312.htm (EX-31.2) — 10KB
- repl-6302024x10qxex321.htm (EX-32.1) — 5KB
- repl-6302024x10qxex322.htm (EX-32.2) — 5KB
- 0001737953-24-000013.txt ( ) — 6829KB
- repl-20240630.xsd (EX-101.SCH) — 57KB
- repl-20240630_cal.xml (EX-101.CAL) — 87KB
- repl-20240630_def.xml (EX-101.DEF) — 205KB
- repl-20240630_lab.xml (EX-101.LAB) — 672KB
- repl-20240630_pre.xml (EX-101.PRE) — 457KB
- repl-20240630_htm.xml (XML) — 795KB
FINANCIAL INFORMATION
PART I FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.
Controls and Procedures
Controls and Procedures 37
OTHER INFORMATION
PART II OTHER INFORMATION 38 Item 1.
Legal Proceedings
Legal Proceedings 38 Item 1A.
Risk Factors
Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 3. Defaults Upon Senior Securities 74 Item 4. Mine Safety Disclosure 74 Item 5. Other Information 74 Item 6. Exhibits 75
SIGNATURES
SIGNATURES 76 2 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share amounts) (Unaudited) June 30, 2024 March 31, 2024 Assets Current assets: Cash and cash equivalents $ 151,658 $ 74,457 Short-term investments 317,466 346,211 Research and development incentives receivable 4,933 4,922 Prepaid expenses and other current assets 6,263 8,077 Total current assets 480,320 433,667 Property, plant and equipment, net 11,403 10,483 Research and development incentives receivable, non-current 438 — Restricted cash 1,700 1,700 Right-to-use asset - operating leases 4,475 4,635 Right-to-use asset - financing leases 36,629 37,237 Total assets $ 534,965 $ 487,722 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 864 $ 2,578 Accrued expenses and other current liabilities 30,914 33,981 Operating lease liabilities, current 1,164 1,161 Financing lease liabilities, current 2,738 2,718 Total current liabilities 35,680 40,438 Operating lease liabilities, non-current 3,600 3,771 Financing lease liabilities, non-current 23,256 23,410 Long term debt, net of discount 45,192 44,809 Other liabilities, non-current 786 786 Total liabilities $ 108,514 $ 113,214 Commitments and contingencies (Note 14) Stockholders' equity Common stock, $ 0.001 par value; 150,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 68,309,968 and 61,415,105 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 68 61 Additional paid-in capital 1,177,113 1,070,874 Accumulated deficit ( 755,054 ) ( 701,282 ) Accumulated other comprehensive income 4,324 4,855 Total stockholders' equity 426,451 374,508 Total liabilities and stockholders' equity $ 534,965 $ 487,722 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED STATEMENTS OF